Quince Therapeutics
QNCX
32 hedge funds and large institutions have $6.96M invested in Quince Therapeutics in 2025 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 6 closing their positions.
1,875% more call options, than puts
Call options by funds: $79K | Put options by funds: $4K
0% more ownership
Funds ownership: 0.06% → 0.06% (+0%)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
0% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 8
3% less funds holding
Funds holding: 33 → 32 (-1)
27% less capital invested
Capital invested by funds: $9.55M → $6.96M (-$2.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
IEQ Capital
Foster City,
California
|
+$1.23M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$282K |
| 3 |
IP
Intellectus Partners
San Francisco,
California
|
+$81.5K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$61.7K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$55.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$156K |
| 2 |
SC
Shay Capital
New York
|
-$141K |
| 3 |
Morgan Stanley
New York
|
-$35.4K |
| 4 |
Renaissance Technologies
New York
|
-$35.1K |
| 5 |
KAS
Kestra Advisory Services
Austin,
Texas
|
-$28.7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
UBS Group
Zurich,
Switzerland
| $939 | -$611 | -2 | -33% |
|
27
JP Morgan Chase
New York
| $728 | – | – | – |
|
|
JFG
28
JDM Financial Group
Austin,
Texas
| $452 | – | – | – |
|
|
PA
29
Parallel Advisors
San Francisco,
California
| $392 | – | – | – |
|
30
Osaic Holdings
Scottsdale,
Arizona
| $368 | -$916 | -3 | -75% |
|
31
Group One Trading
Chicago,
Illinois
| $327 | +$305 | +1 | New |
|
|
HC
32
Hurley Capital
New York
| $161 | – | – | – |
|
|
WIM
33
Westside Investment Management
Santa Monica,
California
| $100 | – | – | – |
|
|
SS
34
SBI Securities
Tokyo,
Japan
| $98 | – | – | – |
|
35
Fidelity Investments
Boston,
Massachusetts
| $67 | – | – | – |
|
36
Barclays
London,
United Kingdom
| $30 | -$305 | -1 | Closed |
|
|
KAS
37
Kestra Advisory Services
Austin,
Texas
| – | -$28.7K | -77 | Closed |
|
38
Jane Street
New York
| – | -$19.6K | -52 | Closed |
|
39
Citigroup
New York
| – | -$9.66K | -26 | Closed |
|
|
TRCT
40
Tower Research Capital (TRC)
New York
| – | -$3.17K | -8 | Closed |
|
|
FA
41
Financial Avengers
Oakland,
California
| – | -$187 | -1 | Closed |
|
QNCX Hedge Fund Activity: Q1 2025 in Review
32 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Quince Therapeutics (QNCX) for Q1 2025, worth a combined $6.96M — down 27% from $9.55M a quarter earlier.
Fund positioning in QNCX was balanced in Q1 2025: 6 funds opened new positions, 6 closed out, 8 added to existing stakes and 8 trimmed.
The largest buyer was IEQ Capital, opening a new position worth an estimated $1.23M. The largest seller was BlackRock, cutting an estimated $156K.
- 32 institutional investors held Quince Therapeutics (QNCX) as of Q1 2025, down from 33 in Q4 2024.
- Funds reported $6.96M of Quince Therapeutics stock for Q1 2025, down 27% quarter-over-quarter.
- 6 funds opened new Quince Therapeutics positions in Q1 2025 and 6 closed out, a net change of 0 holders.
- The largest Quince Therapeutics buyer in Q1 2025 was IEQ Capital, an estimated $1.23M added.
- The largest Quince Therapeutics seller in Q1 2025 was BlackRock, an estimated $156K sold.
Based on aggregated 13F filings for Q1 2025.